Tempus AI

Tempus AI Long-term Debt

The Long-Term Debt of Tempus AI (TEM) as of Nov 20, 2026 is 1.24 B USD. In the previous year, Long-Term Debt was 435.44 M USD — a change of 184.66% (higher).

Long-term Debt

1.24 BUSD

YoY

184.66%

Last updated:

Long-Term Debt of Tempus AI is 2025 1.24 B USD. Long-Term Debt of Tempus AI was 2024 435.44 M USD. It decreases by 184.66% higher compared to the previous year.

The Tempus AI Long-term Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Long-term Debt
Date
Long-term Debt
Jan 1, 2020
250.00 M USD
Jan 1, 2021
238.24 M USD
Jan 1, 2022
389.55 M USD
Jan 1, 2023
449.67 M USD
Jan 1, 2024
435.44 M USD
Jan 1, 2025
1.24 B USD
The Tempus AI Long-term Debt history
YEARLong-term DebtYoY
1.24 BUSD+184.66%
435.44 MUSD-3.16%
449.67 MUSD+15.43%
389.55 MUSD+63.51%
238.24 MUSD-4.71%
250.00 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Tempus AI Stock analysis

What does Tempus AI do? Tempus AI Inc provides next generation diagnostics through genomics, data, and AI applications. Its genomics product line includes next generation sequencing, diagnostics, PCR, profiling, molecular genotyping, and pathology testing. The AI applications focus on algorithmic diagnostics, software as a medical device, and clinical decision support tools. The primary AI product Next uses machine learning to identify care gaps for oncology and cardiology patients. The company serves healthcare providers and life sciences organizations seeking personalized medicine solutions. Tempus AI Inc's revenue comes from its genomics and AI product lines. The genomics services are delivered through its laboratories, offering sequencing, diagnostics, and molecular testing. The AI applications, particularly Next, are sold as software solutions to healthcare institutions. The target customers are healthcare providers and life sciences companies that require advanced diagnostic tools for personalized treatment plans. The company operates in the Life Sciences Tools & Services industry, focusing on oncology and cardiology segments. The company's genomics product line generates revenue through laboratory services for molecular pathology testing. AI applications like Next are sold as medical device software, targeting healthcare institutions for clinical decision support. The primary segments served are oncology and cardiology, where personalized medicine is critical. The company's products are designed to integrate with existing healthcare data systems to improve patient care outcomes. Tempus AI is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tempus AI stock

Long-Term Debt of Tempus AI is 1.24 B USD in 2025.

Long-Term Debt of Tempus AI changed from 435.44 M USD to 1.24 B USD, representing a 184.66% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Long-Term Debt Tempus AI since 2006 – with annual values, charts, and detailed analysis.

Long-term debt represents obligations due after one year. It is a key component of a company's capital structure and leverage.

Long-Term Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Long-Term Debt's Tempus AI historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Tempus AI

All Key Metrics — Tempus AI